Pharma R&D Outsourcing
All research in Pharma R&D Outsourcing — 3 reports.
Samsung Biologics is the world's largest biologics CDMO, a contract development and manufacturing platform that became a pure-play CDMO after spinning off Samsung Bioepis in November 2025. Its core case rests on world-leading capacity of roughly 780,000 liters, operating margin near 45%, revenue growth above 30%, relationships with 17 of the world's top 20 pharmaceutical companies, and a $21.4B backlog, but the valuation already prices in capacity leadership and BIOSECURE upside that has not yet been proven in orders. Report rating Hold: a top-tier compounder deserves a premium, but at the current price the margin of safety is thin.
WuXi AppTec is the global leader in small-molecule CRDMO, with the highest gross margin among peers and core recurring net profit still up 32.6%. The central thesis is that the business quality remains high, but the H-share price of HKD 125.6 sits only inside a neutral valuation band, lacks a margin of safety, and still carries unresolved BIOSECURE/1260H binary geopolitical risk plus ongoing controlling-shareholder selling. Research rating Watch: a high-quality compounder worth monitoring, but current price and unresolved tail risk do not justify a new-position entry.
Charles River Laboratories is a real non-clinical R&D outsourcing platform now moving through portfolio restructuring and regulatory migration. The core thesis is that the current price of about $180.71 sits only near the lower end of neutral value ($180-195), with too little margin of safety, while an ideal entry would require a pullback to $130-150. Report Rating Watch: a credible cash-generative platform, but the recovery and regulatory transition are not yet proven enough for a Buy.